buy priligy online cefalexin tablets 500mg what is the prescription cephalexin used for http://www.codesria.org/?q=1&p...buy-online wellbutrin sr 300 mg single dose
viagra online nederland 
comprar viaga en sevilla 
acquisto cialis generico on line 
http://www.capitalvision.fr/ma...-generique 
cialis generico sicuro 
potenzmittel levitra kaufen viagra naturel pour femme köpa viagra online http://www.javafilms.fr/?comps...s-generika viagra cialis trial packs viagra original sin receta indien viagra que reaccion tiene el viagra viagra vert sildenafil laboratorio chile
    http://he.manhigut.org/?itemid...proscar-uk venlafaxine 37.5 mg slow release spironolactone long term use side effect order proscar online uk propranolol pharmacy uk

Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study

Fri, Nov 8, 2013

Oral Cancer News

Source: The Lancet
Published: September 7, 2013
By: Aimée R Kreimer PhD, Christine M Pierce Campbell PhD, Hui-Yi Lin PhD, William Fulp MS, Mary R Papenfuss MS, Martha Abrahamsen MPH, Prof Allan Hildesheim PhD, Prof Luisa L Villa PhD, Jorge J Salmerón MD, Prof Eduardo Lazcano-Ponce PhD, Prof Anna R Giuliano PhD
 

Summary

Background

Oral human papillomavirus (HPV) infection causes a subset of oropharyngeal cancers. These cancers disproportionately affect men, are increasing in incidence, and have no proven prevention methods. We aimed to establish the natural history of oral HPV infection in men.

Methods

To estimate incidence and clearance of HPV infections, men residing in Brazil, Mexico, and the USA who were HIV negative and reported no history of anogenital cancer were recruited into the HPV Infection in Men (HIM) cohort study. A subset of the cohort who provided two or more oral rinse-and-gargle samples with valid HPV results and who completed a minimum of 2 weeks of follow-up were included in this analysis. Oral rinse-and-gargle samples and questionnaire data were obtained every 6 months for up to 4 years. Samples were analysed for the presence of oncogenic and non-oncogenic HPV infections by the linear array method.

Findings

1626 men aged 18—73 years and with a median follow-up of 12·7 months (IQR 12·1—14·7) were included in the analysis. During the first 12 months of follow-up, 4·4% (95% CI 3·5—5·6; n=115 incident infections) of men acquired an incident oral HPV infection, 1·7% (1·2—2·5; n=53 incident infections) an oral oncogenic HPV infection, and 0·6% (0·3—1·1; n=18 incident infections) an oral HPV 16 infection. Acquisition of oral oncogenic HPV was significantly associated with smoking and not being married or cohabiting, but was similar across countries, age groups, and reported sexual behaviours. Median duration of infection was 6·9 months (95 % CI 6·2—9·3; n=45 cleared infections) for any HPV, 6·3 months (6·0—9·9; n=18 cleared infections) for oncogenic HPV, and 7·3 months (6·0—not estimable; n=5 cleared infections) for HPV 16. Eight of the 18 incident oral HPV 16 infections persisted for two or more study visits.

Interpretation

Newly acquired oral oncogenic HPV infections in healthy men were rare and most were cleared within 1 year. Additional studies into the natural history of HPV are needed to inform development of infection-related prevention efforts.

Funding

US National Cancer Institute, Merck Sharp & Dohme.

* This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

 

Print Friendly
Be Sociable, Share!
, , ,

Leave a Reply

You must be logged in to post a comment.